Pharmaceutical discount agreements
Original notice title
Germany – Pharmaceutical products – Arzneimittelrabattverträge gem. § 130a Abs. 8 SGB V im Rahmen von Open-House-Verfahren
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
30 / 100
Risk factors
No estimated value or minimum turnover is indicated; the actual financial benefit depends on the buyer's prescribing be...
Submission via email with no electronic confirmation system; risk of late submission or missing documents.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Supplies contract
- 3 lots
- Duration until Aug 2026
- Non-exclusive discount agreements (Rabattverträge) for pharmaceutical active substances on a take-it-or-leave-it basis.
- Contract period from 01/09/2024 to 31/08/2026 with possible unilateral extension by the buyer for up to 12 months.
Show full summary
Non-exclusive discount agreement (Open-House) by IKK classic for pharmaceutical active substances (32 lots). Eligible pharmaceutical entrepreneurs can join at any time until 06/07/2026, with standard non-negotiable terms. No estimated value provided; performance in Germany.
Risks
No estimated value or minimum turnover is indicated; the actual financial benefit depends on the buyer's prescribing be...
Submission via email with no electronic confirmation system; risk of late submission or missing documents.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Participation limited to pharmaceutical entrepreneurs (pharmazeutische Unternehmer) as defined in §4 Abs. 18 AMG; consortia of such entrepreneurs also allowed.
Administrative
- Submission via email to [email protected]; electronic submission not allowed (only email).
- Language: German only.
Buyer
Lots (32)
LOT-0001
Aclidiniumbromid; ATC-Code: R03BB05
Discount agreement for Aclidiniumbromid (ATC R03BB05). Non-exclusive, standard terms. Contract period 01/09/2024–31/08/2026, possible extension up to 12 months.
Location
Duration
Category
Deadline
Award details
Selection criteria
Show original TED data
Original TED description
Aclidiniumbromid; ATC-Code: R03BB05
LOT-0002
Anakinra; ATC-Code: L04AC03
Discount agreement for Anakinra (ATC L04AC03). Terms similar to LOT-0001.
Location
Duration
Category
Deadline
Award details
Selection criteria
Show original TED data
Original TED description
Anakinra; ATC-Code: L04AC03
LOT-0003
Chinin; ATC-Code: M09AA02 (ADV); P01BC01 (WHO)
Discount agreement for Chinin. Terms similar.
Location
Duration
Category
Deadline
Award details
Selection criteria
Show original TED data
Original TED description
Chinin; ATC-Code: M09AA02 (ADV); P01BC01 (WHO)
LOT-0004
Dabigatran; ATC-Code: B01AE07
Dabigatran; ATC-Code: B01AE07
Location
Duration
Category
Award details
Selection criteria
LOT-0005
Darbepoetin; ATC-Code: B03XA02
Darbepoetin; ATC-Code: B03XA02
Location
Duration
Category
Award details
Selection criteria
LOT-0006
Dexamfetamin; ATC-Code: N06BA02
Dexamfetamin; ATC-Code: N06BA02
Location
Duration
Category
Award details
Selection criteria
LOT-0007
Dienogest und Estrogen; 2mg / 2 mg; ATC-Code: G03FA15
Dienogest und Estrogen; 2mg / 2 mg; ATC-Code: G03FA15
Location
Duration
Category
Award details
Selection criteria
LOT-0008
Epoetin alfa; ATC-Code: B03XA01
Epoetin alfa; ATC-Code: B03XA01
Location
Duration
Category
Award details
Selection criteria
LOT-0009
Epoetin beta; ATC-Code: B03XA01
Epoetin beta; ATC-Code: B03XA01
Location
Duration
Category
Award details
Selection criteria
LOT-0010
Epoetin theta; ATC-Code: B03XA01
Epoetin theta; ATC-Code: B03XA01
Location
Duration
Category
Award details
Selection criteria
LOT-0011
Epoetin zeta; ATC-Code: B03XA01
Epoetin zeta; ATC-Code: B03XA01
Location
Duration
Category
Award details
Selection criteria
LOT-0012
Felodipin und Ramipril; ATC-Code: C09BB05
Felodipin und Ramipril; ATC-Code: C09BB05
Location
Duration
Category
Award details
Selection criteria
LOT-0013
Fluticason und Formoterol; ATC-Code: R03AK11
Fluticason und Formoterol; ATC-Code: R03AK11
Location
Duration
Category
Award details
Selection criteria
LOT-0014
Hydrocortison; ATC-Code: H02AB09
Hydrocortison; ATC-Code: H02AB09
Location
Duration
Category
Award details
Selection criteria
LOT-0015
Hydrocortisonbutyrat; ATC-Code: D07AB02
Hydrocortisonbutyrat; ATC-Code: D07AB02
Location
Duration
Category
Award details
Selection criteria
LOT-0016
Iloprost ; ATC-Code: C02KX08 (ADV), B01AC11 (WHO)
Iloprost ; ATC-Code: C02KX08 (ADV), B01AC11 (WHO)
Location
Duration
Category
Award details
Selection criteria
LOT-0017
Methylprednisolonaceponat; ATC-Code: D07AC14
Methylprednisolonaceponat; ATC-Code: D07AC14
Location
Duration
Category
Award details
Selection criteria
LOT-0018
Minocyclin; ATC-Code: J01AA08
Minocyclin; ATC-Code: J01AA08
Location
Duration
Category
Award details
Selection criteria
LOT-0019
Minoxidil; ATC-Code: C02DC01
Minoxidil; ATC-Code: C02DC01
Location
Duration
Category
Award details
Selection criteria
LOT-0020
Naloxegol; ATC-Code: A06AH03
Naloxegol; ATC-Code: A06AH03
Location
Duration
Category
Award details
Selection criteria
LOT-0021
Ocrelizumab; ATC-Code: L04AG08
Ocrelizumab; ATC-Code: L04AG08
Location
Duration
Category
Award details
Selection criteria
LOT-0022
Paliperidon parenteral; Wirkstärke ab 175 mg; ATC-Code: N05AX13
Paliperidon parenteral; Wirkstärke ab 175 mg; ATC-Code: N05AX13
Location
Duration
Category
Award details
Selection criteria
LOT-0023
Paliperidon parenteral; Wirkstärke bis 150 mg; ATC-Code: N05AX13
Paliperidon parenteral; Wirkstärke bis 150 mg; ATC-Code: N05AX13
Location
Duration
Category
Award details
Selection criteria
LOT-0024
PEG-Epoetin beta; ATC-Code: B03XA03
PEG-Epoetin beta; ATC-Code: B03XA03
Location
Duration
Category
Award details
Selection criteria
LOT-0025
Pegvisomant; ATC-Code: H01AX01
Pegvisomant; ATC-Code: H01AX01
Location
Duration
Category
Award details
Selection criteria
LOT-0026
Perampanel; ATC-Code: N03AX22
Perampanel; ATC-Code: N03AX22
Location
Duration
Category
Award details
Selection criteria
LOT-0027
Perindopril, Amlodipin und Indapamid; ATC-Code: C09BX01
Perindopril, Amlodipin und Indapamid; ATC-Code: C09BX01
Location
Duration
Category
Award details
Selection criteria
LOT-0028
Ranibizumab; ATC-Code: S01LA04
Ranibizumab; ATC-Code: S01LA04
Location
Duration
Category
Award details
Selection criteria
LOT-0029
Reproterol und Cromoglicinsäure; ATC-Code: R03AK05
Reproterol und Cromoglicinsäure; ATC-Code: R03AK05
Location
Duration
Category
Award details
Selection criteria
LOT-0030
Salmeterol und Fluticason; Inhalationspulver; ATC-Code: R03AK06
Salmeterol und Fluticason; Inhalationspulver; ATC-Code: R03AK06
Location
Duration
Category
Award details
Selection criteria
LOT-0031
Zolmitriptan; Nasenspray; ATC-Code: N02CC03
Zolmitriptan; Nasenspray; ATC-Code: N02CC03
Location
Duration
Category
Award details
Selection criteria
LOT-0032
Golimumab; ATC-Code: L04AB06
Golimumab; ATC-Code: L04AB06
Location
Duration
Category
Award details
Selection criteria
Procurement Details
- Publication date
- 20 sie 2024
- Notice type
- Contract notice — standard
- Languages
- German
Reference metadata
- Notice subtype
- 16
- Notice version
- 1
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 502389-2024
Documents (1)
Similar tenders
Estonia – Underwear – Termopesu ostmine
Poland – Hire of industrial vehicles with driver – Kompleksowa obsługa placów składowych i transportu wewnętrznego na powierzchni (w tym kopalnianych sieci kolei wąskotorowych) na rzecz Polskiej Grupy Górniczej S.A. KWK Murcki - Staszic
France – Development services of real estate – SELECTION D'UN PROJET POUR LA REALISATION D'UN ENSEMBLE IMMOBILIER DE 28 LOGEMENTS COLLECTIFS A CHATENAY-MALABRY (92) EN CPI
Poland – Pipeline, piping, pipes, casing, tubing and related items – „Dostawy rur z tworzyw sztucznych dla Południowego Koncernu Węglowego S.A.”
Austria – Construction supervision services – A01 GEN Knoten Linz – Knoten Haid + A01 ASt Traun/Haid - Örtliche Bauaufsicht E&M
Czechia – Diagnostic agents – Dodávky ZP_IVD – Reagencie a spotřební materiál pro sekvenační analýzu
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
30 / 100
Risk factors
No estimated value or minimum turnover is indicated; the actual financial benefit depends on the buyer's prescribing be...
Submission via email with no electronic confirmation system; risk of late submission or missing documents.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications